Exact Mass: 387.28454020000004
Exact Mass Matches: 387.28454020000004
Found 264 metabolites which its exact mass value is equals to given mass value 387.28454020000004
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
3,5-Didecanoylpyridine
C25H41NO2 (387.31371260000003)
3,5-Didecanoylpyridine is found in herbs and spices. 3,5-Didecanoylpyridine is an alkaloid from Houttuynia cordata (Yu Xing Cao Alkaloid from Houttuynia cordata (Yu Xing Cao). 3,5-Didecanoylpyridine is found in herbs and spices.
2-Hydroxymyristoylcarnitine
C21H41NO5 (387.29845760000006)
2-Hydroxymyristoylcarnitine is an acylcarnitine. More specifically, it is an 2-hydroxymyristic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 2-Hydroxymyristoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 2-hydroxymyristoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. In particular 2-hydroxymyristoylcarnitine is elevated in the blood or plasma of individuals with CVD in type 2 diabetes mellitus (PMID: 32431666). Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews]. A human metabolite taken as a putative food compound of mammalian origin [HMDB]
3-Hydroxytetradecanoyl carnitine
C21H41NO5 (387.29845760000006)
3-Hydroxytetradecanoyl carnitine is an acylcarnitine. More specifically, it is an 3-hydroxytetradecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3-Hydroxytetradecanoyl carnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 3-hydroxytetradecanoyl carnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. In particular 3-hydroxytetradecanoyl carnitine is elevated in the blood or plasma of individuals with CVD in type 2 diabetes mellitus (PMID: 32431666). Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
Tridecanedioylcarnitine
C20H37NO6 (387.26207420000003)
Tridecanedioylcarnitine is an acylcarnitine. More specifically, it is an tridecanedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Tridecanedioylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine Tridecanedioylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
N-Palmitoyl Methionine
C21H41NO3S (387.28069960000005)
N-palmitoyl methionine belongs to the class of compounds known as N-acylamides. These are molecules characterized by a fatty acyl group linked to a primary amine by an amide bond. More specifically, it is a Palmitic acid amide of Methionine. It is believed that there are more than 800 types of N-acylamides in the human body. N-acylamides fall into several categories: amino acid conjugates (e.g., those acyl amides conjugated with amino acids), neurotransmitter conjugates (e.g., those acylamides conjugated with neurotransmitters), ethanolamine conjugates (e.g., those acylamides conjugated to ethanolamine), and taurine conjugates (e.g., those acyamides conjugated to taurine). N-Palmitoyl Methionine is an amino acid conjugate. N-acylamides can be classified into 9 different categories depending on the size of their acyl-group: 1) short-chain N-acylamides; 2) medium-chain N-acylamides; 3) long-chain N-acylamides; and 4) very long-chain N-acylamides; 5) hydroxy N-acylamides; 6) branched chain N-acylamides; 7) unsaturated N-acylamides; 8) dicarboxylic N-acylamides and 9) miscellaneous N-acylamides. N-Palmitoyl Methionine is therefore classified as a long chain N-acylamide. N-acyl amides have a variety of signaling functions in physiology, including in cardiovascular activity, metabolic homeostasis, memory, cognition, pain, motor control and others (PMID: 15655504). N-acyl amides have also been shown to play a role in cell migration, inflammation and certain pathological conditions such as diabetes, cancer, neurodegenerative disease, and obesity (PMID: 23144998; PMID: 25136293; PMID: 28854168).N-acyl amides can be synthesized both endogenously and by gut microbiota (PMID: 28854168). N-acylamides can be biosynthesized via different routes, depending on the parent amine group. N-acyl ethanolamines (NAEs) are formed via the hydrolysis of an unusual phospholipid precursor, N-acyl-phosphatidylethanolamine (NAPE), by a specific phospholipase D. N-acyl amino acids are synthesized via a circulating peptidase M20 domain containing 1 (PM20D1), which can catalyze the bidirectional the condensation and hydrolysis of a variety of N-acyl amino acids. The degradation of N-acylamides is largely mediated by an enzyme called fatty acid amide hydrolase (FAAH), which catalyzes the hydrolysis of N-acylamides into fatty acids and the biogenic amines. Many N-acylamides are involved in lipid signaling system through interactions with transient receptor potential channels (TRP). TRP channel proteins interact with N-acyl amides such as N-arachidonoyl ethanolamide (Anandamide), N-arachidonoyl dopamine and others in an opportunistic fashion (PMID: 23178153). This signaling system has been shown to play a role in the physiological processes involved in inflammation (PMID: 25136293). Other N-acyl amides, including N-oleoyl-glutamine, have also been characterized as TRP channel antagonists (PMID: 29967167). N-acylamides have also been shown to have G-protein-coupled receptors (GPCRs) binding activity (PMID: 28854168). The study of N-acylamides is an active area of research and it is likely that many novel N-acylamides will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered for these molecules.
N-Stearoyl Cysteine
C21H41NO3S (387.28069960000005)
N-stearoyl cysteine belongs to the class of compounds known as N-acylamides. These are molecules characterized by a fatty acyl group linked to a primary amine by an amide bond. More specifically, it is a Stearic acid amide of Cysteine. It is believed that there are more than 800 types of N-acylamides in the human body. N-acylamides fall into several categories: amino acid conjugates (e.g., those acyl amides conjugated with amino acids), neurotransmitter conjugates (e.g., those acylamides conjugated with neurotransmitters), ethanolamine conjugates (e.g., those acylamides conjugated to ethanolamine), and taurine conjugates (e.g., those acyamides conjugated to taurine). N-Stearoyl Cysteine is an amino acid conjugate. N-acylamides can be classified into 9 different categories depending on the size of their acyl-group: 1) short-chain N-acylamides; 2) medium-chain N-acylamides; 3) long-chain N-acylamides; and 4) very long-chain N-acylamides; 5) hydroxy N-acylamides; 6) branched chain N-acylamides; 7) unsaturated N-acylamides; 8) dicarboxylic N-acylamides and 9) miscellaneous N-acylamides. N-Stearoyl Cysteine is therefore classified as a long chain N-acylamide. N-acyl amides have a variety of signaling functions in physiology, including in cardiovascular activity, metabolic homeostasis, memory, cognition, pain, motor control and others (PMID: 15655504). N-acyl amides have also been shown to play a role in cell migration, inflammation and certain pathological conditions such as diabetes, cancer, neurodegenerative disease, and obesity (PMID: 23144998; PMID: 25136293; PMID: 28854168).N-acyl amides can be synthesized both endogenously and by gut microbiota (PMID: 28854168). N-acylamides can be biosynthesized via different routes, depending on the parent amine group. N-acyl ethanolamines (NAEs) are formed via the hydrolysis of an unusual phospholipid precursor, N-acyl-phosphatidylethanolamine (NAPE), by a specific phospholipase D. N-acyl amino acids are synthesized via a circulating peptidase M20 domain containing 1 (PM20D1), which can catalyze the bidirectional the condensation and hydrolysis of a variety of N-acyl amino acids. The degradation of N-acylamides is largely mediated by an enzyme called fatty acid amide hydrolase (FAAH), which catalyzes the hydrolysis of N-acylamides into fatty acids and the biogenic amines. Many N-acylamides are involved in lipid signaling system through interactions with transient receptor potential channels (TRP). TRP channel proteins interact with N-acyl amides such as N-arachidonoyl ethanolamide (Anandamide), N-arachidonoyl dopamine and others in an opportunistic fashion (PMID: 23178153). This signaling system has been shown to play a role in the physiological processes involved in inflammation (PMID: 25136293). Other N-acyl amides, including N-oleoyl-glutamine, have also been characterized as TRP channel antagonists (PMID: 29967167). N-acylamides have also been shown to have G-protein-coupled receptors (GPCRs) binding activity (PMID: 28854168). The study of N-acylamides is an active area of research and it is likely that many novel N-acylamides will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered for these molecules.
Deoxyspergualin
(8R,9R,10R,13S,14S)-3-[2-(Diethylamino)ethoxy]-10,13-dimethyl-1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-one
C25H41NO2 (387.31371260000003)
Tresperimus
Mycestericin F
C21H41NO5 (387.29845760000006)
Mycestericin G
C21H41NO5 (387.29845760000006)
(4SR,4aRS,8RS,8aRS,11aRS,11bRS)-1,2,3,4,4a,5,8,8a,9,11a-decahydro-11a-hydroxy-2-methyl-4a-(4-methyl-3-oxopentyl)-7H-4,11-ethano-8,11b-methanocyclopenta[5,6]oxocino[4,3-c]pyridin-7-one|daphnilongertone
21-O-acetylpaxdaphnine B|methyl (2R,5S,8S,15R)-2-(acetoxymethyl)-5-ethyl-6-azapentacyclo[9.5.1.01,5.02,8.014,17]heptadec-11(17)-ene-15-carboxylate
(9beta,16alpha,20R)-16-hydroxy-4,4,14-trimethyl-20-(methylamino)-9,19-cyclopregnane-3-one
C25H41NO2 (387.31371260000003)
methyl 4-[(E)-2-acetyl-4-oxoundec-1-enyl]-6-propylnicotinate
2-(12-Hydroxy-12-methyltridecyl)-3-methoxyquinolin-4(1H)-one
C24H37NO3 (387.27732920000005)
Gusperimus
L - Antineoplastic and immunomodulating agents > L04 - Immunosuppressants > L04A - Immunosuppressants > L04AA - Selective immunosuppressants D020011 - Protective Agents > D011837 - Radiation-Protective Agents D007155 - Immunologic Factors > D007166 - Immunosuppressive Agents C308 - Immunotherapeutic Agent > C574 - Immunosuppressant D000970 - Antineoplastic Agents D007004 - Hypoglycemic Agents
Ala Ala Lys Val
Ala Ala Val Lys
Ala Gly Ile Lys
Ala Gly Lys Ile
Ala Gly Lys Leu
Ala Gly Leu Lys
Ala Ile Gly Lys
Ala Ile Lys Gly
Ala Lys Ala Val
Ala Lys Gly Ile
Ala Lys Gly Leu
Ala Lys Ile Gly
Ala Lys Leu Gly
Ala Lys Val Ala
Ala Leu Gly Lys
Ala Leu Lys Gly
Ala Val Ala Lys
Ala Val Lys Ala
Gly Ala Ile Lys
Gly Ala Lys Ile
Gly Ala Lys Leu
Gly Ala Leu Lys
Gly Ile Ala Lys
Gly Ile Lys Ala
Gly Lys Ala Ile
Gly Lys Ala Leu
Gly Lys Ile Ala
Gly Lys Leu Ala
Gly Leu Ala Lys
Gly Leu Lys Ala
Ile Ala Gly Lys
Ile Ala Lys Gly
Ile Gly Ala Lys
Ile Gly Lys Ala
Ile Lys Ala Gly
Ile Lys Gly Ala
Lys Ala Ala Val
Lys Ala Gly Ile
Lys Ala Gly Leu
Lys Ala Ile Gly
Lys Ala Leu Gly
Lys Ala Val Ala
Lys Gly Ala Ile
Lys Gly Ala Leu
Lys Gly Ile Ala
Lys Gly Leu Ala
Lys Ile Ala Gly
Lys Ile Gly Ala
Lys Leu Ala Gly
Lys Leu Gly Ala
Lys Val Ala Ala
Leu Ala Gly Lys
Leu Ala Lys Gly
Leu Gly Ala Lys
Leu Gly Lys Ala
Leu Lys Ala Gly
Leu Lys Gly Ala
Val Ala Ala Lys
Val Ala Lys Ala
Val Lys Ala Ala
U-18666A
C25H41NO2 (387.31371260000003)
17-phenyl-trinor-PGF2alpha amide
Type IV cyanolipid 20:2 ester
C25H41NO2 (387.31371260000003)
Type III cyanolipid 20:2 ester
C25H41NO2 (387.31371260000003)
CAR 14:0;O
C21H41NO5 (387.29845760000006)
13-HDHEA
C24H37NO3 (387.27732920000005)
16-HDHEA
C24H37NO3 (387.27732920000005)
4-Hydroxy-alpha1-[[[6-(2-phenylethoxy)hexyl]amino]methyl]-1,3-benzenedimethanol
dimethyl hydrogen phosphorate, compound with 4-tetrapropyleneaniline
C20H38NO4P (387.25383180000006)
2-aminoethanol,2-dodecylbenzenesulfonic acid
C20H37NO4S (387.24431620000007)
TETRA-N-BUTYLAMMONIUM PHENYLTRIFLUOROBORATE
C22H41BF3N (387.32839720000004)
Deoxyspergualin
D020011 - Protective Agents > D011837 - Radiation-Protective Agents D007155 - Immunologic Factors > D007166 - Immunosuppressive Agents D000970 - Antineoplastic Agents D007004 - Hypoglycemic Agents
Barbexaclone
N - Nervous system > N03 - Antiepileptics > N03A - Antiepileptics > N03AA - Barbiturates and derivatives C78272 - Agent Affecting Nervous System > C264 - Anticonvulsant Agent
3beta-(2-(Diethylamino)ethoxy)androst-5-en-17-one
C25H41NO2 (387.31371260000003)
Progesterone 3-carboxymethyloxime
7alpha-Hydroxy-3-oxochol-4-en-24-Oate
C24H35O4- (387.25352100000003)
A bile acid anion that is the conjugate base of 7alpha-hydroxy-3-oxochol-4-en-24-oic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.
(2S)-6-amino-2-[[(2S,3S)-2-[[(2S)-2,6-diaminohexanoyl]amino]-3-methylpentanoyl]amino]hexanoic acid
C18H37N5O4 (387.28454020000004)
N-[3-(1-azepanyl)propyl]-1-[(4-methoxyphenyl)methyl]-5-oxo-3-pyrrolidinecarboxamide
N-ethyl-N-[[(2S,3S,4S)-4-(hydroxymethyl)-3-[4-[(E)-prop-1-enyl]phenyl]azetidin-2-yl]methyl]-2-morpholin-4-ylacetamide
N-ethyl-N-[[(2S,3R,4S)-4-(hydroxymethyl)-3-[4-[(E)-prop-1-enyl]phenyl]azetidin-2-yl]methyl]-2-morpholin-4-ylacetamide
1-[[(2R,3R,4R)-1-acetyl-4-(hydroxymethyl)-3-phenyl-2-azetidinyl]methyl]-1-cyclopentyl-3-propan-2-ylurea
(2S,3S,4R)-2-(hydroxymethyl)-4-[[methyl(propanoyl)amino]methyl]-N-propan-2-yl-3-[4-[(E)-prop-1-enyl]phenyl]azetidine-1-carboxamide
(2R,3R)-2-(hydroxymethyl)-1-(4-oxanylmethyl)-3-phenyl-N-propyl-1,6-diazaspiro[3.3]heptane-6-carboxamide
N-ethyl-N-[[(2R,3S,4R)-4-(hydroxymethyl)-3-[4-[(E)-prop-1-enyl]phenyl]azetidin-2-yl]methyl]-2-morpholin-4-ylacetamide
1-[[(2S,3S,4S)-1-acetyl-4-(hydroxymethyl)-3-phenyl-2-azetidinyl]methyl]-1-cyclopentyl-3-propan-2-ylurea
(2R,3S,4S)-2-(hydroxymethyl)-4-[[methyl(propanoyl)amino]methyl]-N-propan-2-yl-3-[4-[(E)-prop-1-enyl]phenyl]azetidine-1-carboxamide
(2S,3R,4R)-2-(hydroxymethyl)-4-[[methyl(propanoyl)amino]methyl]-N-propan-2-yl-3-[4-[(E)-prop-1-enyl]phenyl]azetidine-1-carboxamide
(2R,3R,4S)-2-(hydroxymethyl)-4-[[methyl(propanoyl)amino]methyl]-N-propan-2-yl-3-[4-[(E)-prop-1-enyl]phenyl]azetidine-1-carboxamide
2-(dimethylamino)-1-[(2S,3R)-2-(hydroxymethyl)-6-(4-oxanylmethyl)-3-phenyl-1,6-diazaspiro[3.3]heptan-1-yl]ethanone
(2S,3R)-2-(hydroxymethyl)-1-(4-oxanylmethyl)-3-phenyl-N-propyl-1,6-diazaspiro[3.3]heptane-6-carboxamide
(2S,3S)-2-(hydroxymethyl)-1-(4-oxanylmethyl)-3-phenyl-N-propyl-1,6-diazaspiro[3.3]heptane-6-carboxamide
(11Z,14Z,17Z,20Z)-hexacosatetraenoate
A polyunsaturated fatty acid anion that is the conjugate base of (11Z,14Z,17Z,20Z)-hexacosatetraenoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.
15-[(3,6-dideoxy-alpha-L-arabino-hexopyranosyl)oxy]pentadecanoate
(14R)-14-[(2R,3R,5R,6S)-3,5-dihydroxy-6-methyloxan-2-yl]oxypentadecanoate
14-[(2R,3R,5R,6S)-3,5-dihydroxy-6-methyloxan-2-yl]oxy-3-oxotetradecanoate
(13R)-13-[(2R,3R,5R,6S)-3,5-dihydroxy-6-methyloxan-2-yl]oxy-3-oxotetradecanoate
3-hydroxytetradecanoylcarnitine
C21H41NO5 (387.29845760000006)
An O-acylcarnitine having 3-hydroxytetradecanoyl as the acyl substituent.
3-[2-(Diethylamino)ethoxy]-10,13-dimethyl-1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-one
C25H41NO2 (387.31371260000003)
hexacosatetraenoate
A polyunsaturated fatty acid anion that is the conjugate base of hexacosatetraenoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.
oscr#26(1-)
A hydroxy fatty acid ascaroside anion that is the conjugate base of oscr#26, obtained by deprotonation of the carboxy group; major species at pH 7.3.
CarE(14:0)
C21H41NO5 (387.29845760000006)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
2,2,2-trifluoro-1-{2-methyl-3-[(7z)-pentadec-7-en-1-yl]-4,5-dihydropyrrol-1-yl}ethanone
C22H36F3NO (387.27488420000003)
methyl (1r,2r,5s,8s,14r,15r)-2-[(acetyloxy)methyl]-5-ethyl-6-azapentacyclo[9.5.1.0¹,⁵.0²,⁸.0¹⁴,¹⁷]heptadec-11(17)-ene-15-carboxylate
(2e,4e,6z,8e,10e,12s,13r,14e)-13-hydroxy-n-[(2r)-1-hydroxypropan-2-yl]-2,10,12,14-tetramethylheptadeca-2,4,6,8,10,14-hexaenimidic acid
C24H37NO3 (387.27732920000005)
13-hydroxy-n-(1-hydroxypropan-2-yl)-2,10,12,14-tetramethylheptadeca-2,4,6,8,10,14-hexaenimidic acid
C24H37NO3 (387.27732920000005)
n-(6,12-dihydroxy-3,9,15,17-tetramethyl-16-oxocycloheptadeca-2,4,8,10,14-pentaen-1-yl)ethanimidic acid
(2e,4e,6e,8e,10e,14e)-13-hydroxy-n-(1-hydroxypropan-2-yl)-2,10,12,14-tetramethylheptadeca-2,4,6,8,10,14-hexaenimidic acid
C24H37NO3 (387.27732920000005)
methyl 4-(2-acetyl-4-oxoundec-1-en-1-yl)-6-propylpyridine-3-carboxylate
methyl 3-[(2r,3s,4s,8s,11s,13r,16s,17r,19r)-11-hydroxy-13,17-dimethyl-1-azahexacyclo[9.7.1.0²,¹⁶.0³,¹³.0⁴,⁸.0⁸,¹⁹]nonadecan-3-yl]propanoate
C24H37NO3 (387.27732920000005)
methyl (1'r,3r,5's,6s)-6-ethyl-6-hydroxy-3'-methyl-3'-azaspiro[oxane-3,15'-tetracyclo[6.5.1.1¹,⁵.0¹¹,¹⁴]pentadecane]-8'(14'),11'-diene-12'-carboxylate
methyl 4-[(1e)-2-acetyl-4-oxoundec-1-en-1-yl]-6-propylpyridine-3-carboxylate
(2e,4e,6e,8e,10z,12r,13r,14e)-13-hydroxy-n-[(2s)-1-methoxypropan-2-yl]-2,10,12,14-tetramethylhexadeca-2,4,6,8,10,14-hexaenimidic acid
C24H37NO3 (387.27732920000005)
(1s,3r,8r,11s,12s,14r,15s,16r)-14-hydroxy-7,7,12,16-tetramethyl-15-[(1r)-1-(methylamino)ethyl]pentacyclo[9.7.0.0¹,³.0³,⁸.0¹²,¹⁶]octadecan-6-one
C25H41NO2 (387.31371260000003)
(2e,4e)-13-hydroxy-n-(1-hydroxypropan-2-yl)-2,10,12,14-tetramethylheptadeca-2,4,6,8,10,14-hexaenimidic acid
C24H37NO3 (387.27732920000005)
methyl 6-ethyl-6-hydroxy-3'-methyl-3'-azaspiro[oxane-3,15'-tetracyclo[6.5.1.1¹,⁵.0¹¹,¹⁴]pentadecane]-8'(14'),11'-diene-12'-carboxylate
2-[(1-hydroxy-4,6-dimethyldodeca-2,4-dien-1-ylidene)amino]-3-(4-hydroxyphenyl)propanoic acid
methyl (1r,3r,4s,10s,14s,15r,17s,18s,19r)-17,19-dihydroxy-14,18-dimethyl-12-azahexacyclo[10.6.1.1¹,⁴.0¹⁰,¹⁸.0¹⁵,¹⁹.0⁷,²⁰]icos-7(20)-ene-3-carboxylate
1-[14-hydroxy-7,7,12,16-tetramethyl-6-(methylamino)pentacyclo[9.7.0.0¹,³.0³,⁸.0¹²,¹⁶]octadecan-15-yl]ethanone
C25H41NO2 (387.31371260000003)
methyl (1r,3s,4r,10s,14s,15r,17r,18s,19r)-17,19-dihydroxy-14,18-dimethyl-12-azahexacyclo[10.6.1.1¹,⁴.0¹⁰,¹⁸.0¹⁵,¹⁹.0⁷,²⁰]icos-7(20)-ene-3-carboxylate
2-{[(2e,4e,6r)-1-hydroxy-4,6-dimethyldodeca-2,4-dien-1-ylidene]amino}-3-(4-hydroxyphenyl)propanoic acid
methyl (1's,3r,5's,6s)-6-ethyl-6-hydroxy-3'-methyl-3'-azaspiro[oxane-3,15'-tetracyclo[6.5.1.1¹,⁵.0¹¹,¹⁴]pentadecane]-8'(14'),11'-diene-12'-carboxylate
5-[(3,7-dimethylocta-2,6-dien-1-yl)oxy]-2-(2-hydroxyethyl)-7-methoxy-3,6-dimethyl-3h-isoindol-1-one
n-[(1s,2e,4e,6r,8e,10e,12s,14e,17s)-6,12-dihydroxy-3,9,15,17-tetramethyl-16-oxocycloheptadeca-2,4,8,10,14-pentaen-1-yl]ethanimidic acid
(2s)-3-hydroxy-2-{[(2e,4e,6e,8e)-1-hydroxy-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraen-1-ylidene]amino}propanoic acid
(2s,4z)-4-{[(1s,2r,4as,6r,8ar)-1,3,6-trimethyl-2-[(1e)-prop-1-en-1-yl]-4a,5,6,7,8,8a-hexahydro-2h-naphthalen-1-yl](hydroxy)methylidene}-5-hydroxy-2-[(1r)-1-hydroxyethyl]-2h-pyrrol-3-one
1-[(1s,3r,6s,8r,11r,12s,14r,15r,16r)-14-hydroxy-7,7,12,16-tetramethyl-6-(methylamino)pentacyclo[9.7.0.0¹,³.0³,⁸.0¹²,¹⁶]octadecan-15-yl]ethanone
C25H41NO2 (387.31371260000003)
n-[(1s,2e,4e,6r,8e,10e,12s,14e,17r)-6,12-dihydroxy-3,9,15,17-tetramethyl-16-oxocycloheptadeca-2,4,8,10,14-pentaen-1-yl]ethanimidic acid
(8e,10e)-13-hydroxy-n-(1-methoxypropan-2-yl)-2,10,12,14-tetramethylhexadeca-2,4,6,8,10,14-hexaenimidic acid
C24H37NO3 (387.27732920000005)
2-(12-hydroxy-12-methyltridecyl)-3-methoxy-3h-quinolin-4-one
C24H37NO3 (387.27732920000005)
13-hydroxy-n-(1-methoxypropan-2-yl)-2,10,12,14-tetramethylhexadeca-2,4,6,8,10,14-hexaenimidic acid
C24H37NO3 (387.27732920000005)
methyl 17,19-dihydroxy-14,18-dimethyl-12-azahexacyclo[10.6.1.1¹,⁴.0¹⁰,¹⁸.0¹⁵,¹⁹.0⁷,²⁰]icos-7(20)-ene-3-carboxylate
methyl 3-{11-hydroxy-13,17-dimethyl-1-azahexacyclo[9.7.1.0²,¹⁶.0³,¹³.0⁴,⁸.0⁸,¹⁹]nonadecan-3-yl}propanoate
C24H37NO3 (387.27732920000005)
(2e,4e,6z,8e,10e,12r,13r,14e)-13-hydroxy-n-[(2s)-1-hydroxypropan-2-yl]-2,10,12,14-tetramethylheptadeca-2,4,6,8,10,14-hexaenimidic acid
C24H37NO3 (387.27732920000005)
(2e,4e,6z,8e,10e,12r,13r,14e)-13-hydroxy-n-[(2s)-1-methoxypropan-2-yl]-2,10,12,14-tetramethylhexadeca-2,4,6,8,10,14-hexaenimidic acid
C24H37NO3 (387.27732920000005)
(2s)-2-{[(2e,4e,6r)-1-hydroxy-4,6-dimethyldodeca-2,4-dien-1-ylidene]amino}-3-(4-hydroxyphenyl)propanoic acid
2-(12-hydroxy-12-methyltridecyl)-3-methoxy-1h-quinolin-4-one
C24H37NO3 (387.27732920000005)
1-[(1s,3r,6s,8r,11s,12s,14r,15r,16r)-14-hydroxy-7,7,12,16-tetramethyl-6-(methylamino)pentacyclo[9.7.0.0¹,³.0³,⁸.0¹²,¹⁶]octadecan-15-yl]ethanone
C25H41NO2 (387.31371260000003)
(2e,4e,6e,8e,10e,12r,13r,14e)-13-hydroxy-n-[(2s)-1-methoxypropan-2-yl]-2,10,12,14-tetramethylhexadeca-2,4,6,8,10,14-hexaenimidic acid
C24H37NO3 (387.27732920000005)
2,2,2-trifluoro-1-[2-methyl-3-(pentadec-7-en-1-yl)-4,5-dihydropyrrol-1-yl]ethanone
C22H36F3NO (387.27488420000003)